KR102009932B1 - 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린 - Google Patents

허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린 Download PDF

Info

Publication number
KR102009932B1
KR102009932B1 KR1020147016261A KR20147016261A KR102009932B1 KR 102009932 B1 KR102009932 B1 KR 102009932B1 KR 1020147016261 A KR1020147016261 A KR 1020147016261A KR 20147016261 A KR20147016261 A KR 20147016261A KR 102009932 B1 KR102009932 B1 KR 102009932B1
Authority
KR
South Korea
Prior art keywords
injection
composition
subject
neurons
apoequarine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147016261A
Other languages
English (en)
Korean (ko)
Other versions
KR20140097369A (ko
Inventor
마크 와이. 언더우드
제임스 알. 모이어
Original Assignee
퀸시 바이오사이언스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퀸시 바이오사이언스 엘엘씨 filed Critical 퀸시 바이오사이언스 엘엘씨
Publication of KR20140097369A publication Critical patent/KR20140097369A/ko
Application granted granted Critical
Publication of KR102009932B1 publication Critical patent/KR102009932B1/ko
Assigned to 스틸워터스 바이오사이언스 그룹, 엘엘씨 reassignment 스틸워터스 바이오사이언스 그룹, 엘엘씨 권리의 전부이전등록 Assignors: 퀸시 바이오사이언스 엘엘씨
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147016261A 2011-11-15 2012-11-15 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린 Active KR102009932B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559816P 2011-11-15 2011-11-15
US61/559,816 2011-11-15
PCT/US2012/065291 WO2013074798A1 (en) 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia

Publications (2)

Publication Number Publication Date
KR20140097369A KR20140097369A (ko) 2014-08-06
KR102009932B1 true KR102009932B1 (ko) 2019-08-12

Family

ID=47295186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147016261A Active KR102009932B1 (ko) 2011-11-15 2012-11-15 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린

Country Status (23)

Country Link
US (1) US20140294874A1 (https=)
EP (1) EP2780027B1 (https=)
JP (1) JP6181061B2 (https=)
KR (1) KR102009932B1 (https=)
CN (1) CN104244966B (https=)
AU (1) AU2012340446B2 (https=)
BR (1) BR112014011630A2 (https=)
CA (1) CA2855719C (https=)
CY (1) CY1119300T1 (https=)
DK (1) DK2780027T3 (https=)
ES (1) ES2643392T3 (https=)
HR (1) HRP20171532T1 (https=)
HU (1) HUE035017T2 (https=)
IL (1) IL232494B (https=)
IN (1) IN2014CN04009A (https=)
LT (1) LT2780027T (https=)
MX (1) MX350259B (https=)
PL (1) PL2780027T3 (https=)
PT (1) PT2780027T (https=)
SG (1) SG11201402364WA (https=)
SI (1) SI2780027T1 (https=)
WO (1) WO2013074798A1 (https=)
ZA (1) ZA201403577B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
KR20180001229A (ko) 2016-06-27 2018-01-04 삼성에스디아이 주식회사 이차 전지의 제조 방법 및 이를 이용한 이차 전지
SI3515212T1 (sl) * 2016-09-23 2024-10-30 Quincy Bioscience Llc Sestavki, ki vsebujejo apoaequorin in vitamin d, ter načini njihove uporabe
RU2642961C1 (ru) * 2017-02-21 2018-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии головного мозга

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
BRPI0909435A2 (pt) * 2008-03-11 2017-06-13 Quincy Bioscience Llc composição e método para tratar de um sintoma ou distúrbio associado com o desequilíbrio do cálcio, uso da apoequorina, e, apoaequorina
JP5919604B2 (ja) * 2008-08-08 2016-05-18 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗膵癌抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Also Published As

Publication number Publication date
BR112014011630A2 (pt) 2017-06-27
DK2780027T3 (en) 2017-09-25
IL232494B (en) 2019-03-31
LT2780027T (lt) 2017-10-25
HUE035017T2 (en) 2018-03-28
HK1202417A1 (en) 2015-10-02
ZA201403577B (en) 2015-07-29
NZ624736A (en) 2016-05-27
SG11201402364WA (en) 2014-09-26
EP2780027B1 (en) 2017-07-19
MX350259B (es) 2017-08-31
AU2012340446B2 (en) 2017-08-31
IL232494A0 (en) 2014-06-30
US20140294874A1 (en) 2014-10-02
HRP20171532T1 (hr) 2017-11-17
CY1119300T1 (el) 2018-02-14
CA2855719A1 (en) 2013-05-23
ES2643392T3 (es) 2017-11-22
AU2012340446A1 (en) 2014-05-29
PL2780027T3 (pl) 2017-11-30
CA2855719C (en) 2021-10-26
JP6181061B2 (ja) 2017-08-16
JP2014533692A (ja) 2014-12-15
EP2780027A1 (en) 2014-09-24
PT2780027T (pt) 2017-10-04
KR20140097369A (ko) 2014-08-06
CN104244966A (zh) 2014-12-24
CN104244966B (zh) 2019-01-11
SI2780027T1 (sl) 2017-11-30
MX2014005798A (es) 2014-05-30
WO2013074798A1 (en) 2013-05-23
IN2014CN04009A (https=) 2015-10-23

Similar Documents

Publication Publication Date Title
JP2018514589A5 (https=)
KR20190073365A (ko) 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
KR102009932B1 (ko) 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린
US10493126B2 (en) Combination therapy for ameliorating adverse side effects caused by chemotherapy
US20210030678A1 (en) Cannabinoid and cbd liposome formulations and uses thereof
US9333191B2 (en) Mast cell stabilizers to prevent or treat laminitis
EP2424527B1 (en) Mast cell stabilizers to prevent or treat laminitis
CA3031083A1 (en) Uses of il-12 as a replacement immunotherapeutic
JP2017535607A (ja) アポエクオリン含有組成物および神経細胞の炎症を治療するためのアポエクオリンの使用方法
EP4142704A1 (en) Compositions and methods for treating cytokine storms
HK1202417B (en) Apoaequorin for reducing neuronal injury due to ischemia
NZ624736B2 (en) Apoaequorin for reducing neuronal injury due to ischemia
CN115944621A (zh) 金雀异黄酮在制备预防或治疗白细胞减少症药物中的应用
KR101213070B1 (ko) 포스포리파아제 ｄ１억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물
Mahoney Effects of 5-fluorouracil chemotherapy on fatigue and inflammation in mice: Benefits of quercetin
Hélène Exercise as an Anti‐inflammatory Therapy for Cancer Cachexia: A Focus on

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140613

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171114

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190611

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190806

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190806

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220720

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220720

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230712

Start annual number: 5

End annual number: 5